1
|
Persaud AT, Khela J, Fernandes C, Chaphekar D, Burnie J, Tang VA, Colpitts CC, Guzzo C. Virion-incorporated CD14 enables HIV-1 to bind LPS and initiate TLR4 signaling in immune cells. J Virol 2024; 98:e0036324. [PMID: 38661384 DOI: 10.1128/jvi.00363-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2024] [Accepted: 04/01/2024] [Indexed: 04/26/2024] Open
Abstract
HIV-1 has a broad range of nuanced interactions with the immune system, and the incorporation of cellular proteins by nascent virions continues to redefine our understanding of the virus-host relationship. Proteins located at the sites of viral egress can be selectively incorporated into the HIV-1 envelope, imparting new functions and phenotypes onto virions, and impacting viral spread and disease. Using virion capture assays and western blot, we show that HIV-1 can incorporate the myeloid antigen CD14 into its viral envelope. Virion-incorporated CD14 remained biologically active and able to bind its natural ligand, bacterial lipopolysaccharide (LPS), as demonstrated by flow virometry and immunoprecipitation assays. Using a Toll-like receptor 4 (TLR4) reporter cell line, we also demonstrated that virions with bound LPS can trigger TLR4 signaling to activate transcription factors that regulate inflammatory gene expression. Complementary assays with THP-1 monocytes demonstrated enhanced secretion of inflammatory cytokines like tumor necrosis factor alpha (TNF-α) and the C-C chemokine ligand 5 (CCL5), when exposed to LPS-loaded virus. These data highlight a new type of interplay between HIV-1 and the myeloid cell compartment, a previously well-established cellular contributor to HIV-1 pathogenesis and inflammation. Persistent gut inflammation is a hallmark of chronic HIV-1 infection, and contributing to this effect is the translocation of microbes across the gut epithelium. Our data herein provide proof of principle that virion-incorporated CD14 could be a novel mechanism through which HIV-1 can drive chronic inflammation, facilitated by HIV-1 particles binding bacterial LPS and initiating inflammatory signaling in TLR4-expressing cells.IMPORTANCEHIV-1 establishes a lifelong infection accompanied by numerous immunological changes. Inflammation of the gut epithelia, exacerbated by the loss of mucosal T cells and cytokine dysregulation, persists during HIV-1 infection. Feeding back into this loop of inflammation is the translocation of intestinal microbes across the gut epithelia, resulting in the systemic dissemination of bacterial antigens, like lipopolysaccharide (LPS). Our group previously demonstrated that the LPS receptor, CD14, can be readily incorporated by HIV-1 particles, supporting previous clinical observations of viruses derived from patient plasma. We now show that CD14 can be incorporated by several primary HIV-1 isolates and that this virion-incorporated CD14 can remain functional, enabling HIV-1 to bind to LPS. This subsequently allowed CD14+ virions to transfer LPS to monocytic cells, eliciting pro-inflammatory signaling and cytokine secretion. We posit here that virion-incorporated CD14 is a potential contributor to the dysregulated immune responses present in the setting of HIV-1 infection.
Collapse
Affiliation(s)
- Arvin T Persaud
- Department of Biological Sciences, University of Toronto Scarborough, Toronto, Ontario, Canada
- Department of Cell and Systems Biology, University of Toronto, Toronto, Ontario, Canada
| | - Jasmin Khela
- Department of Biological Sciences, University of Toronto Scarborough, Toronto, Ontario, Canada
| | - Claire Fernandes
- Department of Biological Sciences, University of Toronto Scarborough, Toronto, Ontario, Canada
- Department of Cell and Systems Biology, University of Toronto, Toronto, Ontario, Canada
| | - Deepa Chaphekar
- Department of Biological Sciences, University of Toronto Scarborough, Toronto, Ontario, Canada
- Department of Cell and Systems Biology, University of Toronto, Toronto, Ontario, Canada
| | - Jonathan Burnie
- Department of Biological Sciences, University of Toronto Scarborough, Toronto, Ontario, Canada
- Department of Cell and Systems Biology, University of Toronto, Toronto, Ontario, Canada
| | - Vera A Tang
- Flow Cytometry and Virometry Core Facility, Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada
| | - Che C Colpitts
- Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada
| | - Christina Guzzo
- Department of Biological Sciences, University of Toronto Scarborough, Toronto, Ontario, Canada
- Department of Cell and Systems Biology, University of Toronto, Toronto, Ontario, Canada
- Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
2
|
Belkina AC, Roe CE, Tang VA, Back JB, Bispo C, Conway A, Chakraborty U, Daniels KT, de la Cruz G, Ferrer-Font L, Filby A, Gravano DM, Gregory MD, Hall C, Kukat C, Mozes A, Ordoñez-Rueda D, Orlowski-Oliver E, Pesce I, Porat Z, Poulton NJ, Reifel KM, Rieger AM, Sheridan RTC, Van Isterdael G, Walker RV. Guidelines for establishing a cytometry laboratory. Cytometry A 2024; 105:88-111. [PMID: 37941128 DOI: 10.1002/cyto.a.24807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Revised: 08/10/2023] [Accepted: 10/03/2023] [Indexed: 11/10/2023]
Abstract
The purpose of this document is to provide guidance for establishing and maintaining growth and development of flow cytometry shared resource laboratories. While the best practices offered in this manuscript are not intended to be universal or exhaustive, they do outline key goals that should be prioritized to achieve operational excellence and meet the needs of the scientific community. Additionally, this document provides information on available technologies and software relevant to shared resource laboratories. This manuscript builds on the work of Barsky et al. 2016 published in Cytometry Part A and incorporates recent advancements in cytometric technology. A flow cytometer is a specialized piece of technology that require special care and consideration in its housing and operations. As with any scientific equipment, a thorough evaluation of the location, space requirements, auxiliary resources, and support is crucial for successful operation. This comprehensive resource has been written by past and present members of the International Society for Advancement of Cytometry (ISAC) Shared Resource Laboratory (SRL) Emerging Leaders Program https://isac-net.org/general/custom.asp?page=SRL-Emerging-Leaders with extensive expertise in managing flow cytometry SRLs from around the world in different settings including academia and industry. It is intended to assist in establishing a new flow cytometry SRL, re-purposing an existing space into such a facility, or adding a flow cytometer to an individual lab in academia or industry. This resource reviews the available cytometry technologies, the operational requirements, and best practices in SRL staffing and management.
Collapse
Affiliation(s)
- Anna C Belkina
- Flow Cytometry Core Facility, School of Medicine, Boston University, Boston, Massachusetts, USA
| | - Caroline E Roe
- Cancer and Immunology Core, Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee, USA
| | - Vera A Tang
- Faculty of Medicine, Department of Biochemistry, Microbiology, and Immunology, Flow Cytometry Core Facility, University of Ottawa, Ottawa, Ontario, Canada
| | - Jessica B Back
- Department of Oncology, Wayne State University, Detroit, Michigan, USA
| | - Claudia Bispo
- Flow Cytometry Core Lab, AbbVie Inc, South San Francisco, California, USA
| | | | - Uttara Chakraborty
- Manipal Institute of Regenerative Medicine, Bengaluru, Manipal Academy of Higher Education, Manipal, Karnataka, India
| | | | - Gelo de la Cruz
- Flow Cytometry Platform, Novo Nordisk Foundation Center for Stem Cell Medicine - reNEW, Copenhagen, Denmark
| | - Laura Ferrer-Font
- Hugh Green Cytometry Centre, Malaghan Institute of Medical Research, Wellington, New Zealand
| | - Andrew Filby
- Flow Cytometry Core Facility and Innovation, Methodology and Application Research Theme, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
| | - David M Gravano
- Stem Cell Instrumentation Foundry, University of California Merced, Merced, California, USA
| | - Michael D Gregory
- Cleveland Clinic, Florida Research and Innovation Center, Port St. Lucie, Florida, USA
| | - Christopher Hall
- Flow Cytometry Facility, Babraham Institute, Babraham Research Campus, Cambridge, UK
| | - Christian Kukat
- FACS & Imaging Core Facility, Max Planck Institute for Biology of Ageing, Cologne, Germany
| | - André Mozes
- Flow Cytometry Platform, Champalimaud Foundation, Lisbon, Portugal
| | - Diana Ordoñez-Rueda
- Flow Cytometry Core Facility, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
| | | | - Isabella Pesce
- Cell Analysis and Separation Core Facility, Department of Cellular Computational and Integrative Biology, University of Trento, Trento, Italy
| | - Ziv Porat
- Flow Cytometry Unit, Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel
| | - Nicole J Poulton
- Center for Aquatic Cytometry, Bigelow Laboratory for Ocean Sciences, East Boothbay, Maine, USA
| | - Kristen M Reifel
- Flow Cytometry Core Facility, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA
| | - Aja M Rieger
- Flow Cytometry Core Facility, University of Alberta, Alberta, Canada
| | | | - Gert Van Isterdael
- VIB Flow Core, VIB Center for Inflammation Research, Belgium & Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
| | - Rachael V Walker
- Flow Cytometry Facility, Babraham Institute, Babraham Research Campus, Cambridge, UK
| |
Collapse
|
3
|
Burnie J, Fernandes C, Chaphekar D, Wei D, Ahmed S, Persaud AT, Khader N, Cicala C, Arthos J, Tang VA, Guzzo C. Identification of CD38, CD97, and CD278 on the HIV surface using a novel flow virometry screening assay. Sci Rep 2023; 13:23025. [PMID: 38155248 PMCID: PMC10754950 DOI: 10.1038/s41598-023-50365-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Accepted: 12/19/2023] [Indexed: 12/30/2023] Open
Abstract
While numerous cellular proteins in the HIV envelope are known to alter virus infection, methodology to rapidly phenotype the virion surface in a high throughput, single virion manner is lacking. Thus, many human proteins may exist on the virion surface that remain undescribed. Herein, we developed a novel flow virometry screening assay to discover new proteins on the surface of HIV particles. By screening a CD4+ T cell line and its progeny virions, along with four HIV isolates produced in primary cells, we discovered 59 new candidate proteins in the HIV envelope that were consistently detected across diverse HIV isolates. Among these discoveries, CD38, CD97, and CD278 were consistently present at high levels on virions when using orthogonal techniques to corroborate flow virometry results. This study yields new discoveries about virus biology and demonstrates the utility and feasibility of a novel flow virometry assay to phenotype individual virions.
Collapse
Affiliation(s)
- Jonathan Burnie
- Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON, Canada
- Department of Cell and Systems Biology, University of Toronto, 25 Harbord Street, Toronto, ON, Canada
| | - Claire Fernandes
- Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON, Canada
- Department of Cell and Systems Biology, University of Toronto, 25 Harbord Street, Toronto, ON, Canada
| | - Deepa Chaphekar
- Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON, Canada
- Department of Cell and Systems Biology, University of Toronto, 25 Harbord Street, Toronto, ON, Canada
| | - Danlan Wei
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Shubeen Ahmed
- Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON, Canada
| | - Arvin Tejnarine Persaud
- Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON, Canada
- Department of Cell and Systems Biology, University of Toronto, 25 Harbord Street, Toronto, ON, Canada
| | - Nawrah Khader
- Department of Cell and Systems Biology, University of Toronto, 25 Harbord Street, Toronto, ON, Canada
| | - Claudia Cicala
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - James Arthos
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Vera A Tang
- Flow Cytometry and Virometry Core Facility, Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, 451 Smyth Road, Ottawa, ON, Canada
| | - Christina Guzzo
- Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON, Canada.
- Department of Cell and Systems Biology, University of Toronto, 25 Harbord Street, Toronto, ON, Canada.
| |
Collapse
|
4
|
Cook S, Tang VA, Lannigan J, Jones JC, Welsh JA. Quantitative flow cytometry enables end-to-end optimization of cross-platform extracellular vesicle studies. Cell Rep Methods 2023; 3:100664. [PMID: 38113854 PMCID: PMC10753385 DOI: 10.1016/j.crmeth.2023.100664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/18/2023] [Revised: 07/28/2023] [Accepted: 11/15/2023] [Indexed: 12/21/2023]
Abstract
Flow cytometry (FCM) is a common method for characterizing extracellular particles (EPs), including viruses and extracellular vesicles (EVs). Frameworks such as MIFlowCyt-EV exist to provide reporting guidelines for metadata, controls, and data reporting. However, tools to optimize FCM for EP analysis in a systematic and quantitative way are lacking. Here, we demonstrate a cohesive set of methods and software tools that optimize FCM settings and facilitate cross-platform comparisons for EP studies. We introduce an automated small-particle optimization (SPOT) pipeline to optimize FCM fluorescence and light scatter detector settings for EP analysis and leverage quantitative FCM (qFCM) as a tool to further enable FCM optimization of fluorophore panel selection, laser power, pulse statistics, and window extensions. Finally, we demonstrate the value of qFCM to facilitate standardized cross-platform comparisons, irrespective of instrument configuration, settings, and sensitivity, in a cross-platform standardization study utilizing a commercially available EV reference material.
Collapse
Affiliation(s)
- Sean Cook
- Laboratory of Pathology, Translational Nanobiology Section, Centre for Cancer Research, National Institute of Health, National Institutes of Health, Bethesda, MD, USA
| | - Vera A Tang
- Faculty of Medicine, Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Flow Cytometry and Virometry Core Facility, Ottawa, ON K1H 8M5, Canada
| | | | - Jennifer C Jones
- Laboratory of Pathology, Translational Nanobiology Section, Centre for Cancer Research, National Institute of Health, National Institutes of Health, Bethesda, MD, USA
| | - Joshua A Welsh
- Laboratory of Pathology, Translational Nanobiology Section, Centre for Cancer Research, National Institute of Health, National Institutes of Health, Bethesda, MD, USA.
| |
Collapse
|
5
|
Pleet M, Cook S, Tang VA, Stack E, Ford VJ, Lannigan J, Do N, Wenger E, Fraikin JL, Jacobson S, Jones JC, Welsh JA. Extracellular Vesicle Refractive Index Derivation Utilizing Orthogonal Characterization. Nano Lett 2023; 23:9195-9202. [PMID: 37788377 PMCID: PMC10603804 DOI: 10.1021/acs.nanolett.3c00562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/12/2023] [Revised: 07/24/2023] [Indexed: 10/05/2023]
Abstract
The analysis of small particles, including extracellular vesicles and viruses, is contingent on their ability to scatter sufficient light to be detected. These detection methods include flow cytometry, nanoparticle tracking analysis, and single particle reflective image sensing. To standardize measurements and enable orthogonal comparisons between platforms, a quantifiable limit of detection is required. The main parameters that dictate the amount of light scattered by particles include size, morphology, and refractive index. To date, there has been a lack of accessible techniques for measuring the refractive index of nanoparticles at a single-particle level. Here, we demonstrate two methods of deriving a small particle refractive index using orthogonal measurements with commercially available platforms. These methods can be applied at either a single-particle or population level, enabling the integration of diameter and scattering cross section values to derive the refractive index using Mie theory.
Collapse
Affiliation(s)
- Michelle
L. Pleet
- Viral
Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National
Institutes of Health, Bethesda, Maryland 20892, United States
| | - Sean Cook
- Laboratory
of Pathology, Translational Nanobiology Section, Centre for Cancer
Research, National Institutes of Health, Bethesda, Maryland 20892, United States
| | - Vera A. Tang
- Faculty
of Medicine, Department of Biochemistry, Microbiology, and Immunology, University of Ottawa Flow Cytometry & Virometry
Core Facility, Ottawa, Ontario K1H 8M5, Canada
| | - Emily Stack
- Viral
Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National
Institutes of Health, Bethesda, Maryland 20892, United States
| | - Verity J. Ford
- Critical
Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 United States
| | - Joanne Lannigan
- Flow
Cytometry Support Services, Alexandria, Virginia 22314, United States
| | - Ngoc Do
- Spectradyne, Signal Hill, California 90755, United States
| | - Ellie Wenger
- Spectradyne, Signal Hill, California 90755, United States
| | | | - Steven Jacobson
- Viral
Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National
Institutes of Health, Bethesda, Maryland 20892, United States
| | - Jennifer C. Jones
- Laboratory
of Pathology, Translational Nanobiology Section, Centre for Cancer
Research, National Institutes of Health, Bethesda, Maryland 20892, United States
| | - Joshua A. Welsh
- Laboratory
of Pathology, Translational Nanobiology Section, Centre for Cancer
Research, National Institutes of Health, Bethesda, Maryland 20892, United States
| |
Collapse
|
6
|
Welsh JA, Arkesteijn GJA, Bremer M, Cimorelli M, Dignat-George F, Giebel B, Görgens A, Hendrix A, Kuiper M, Lacroix R, Lannigan J, van Leeuwen TG, Lozano-Andrés E, Rao S, Robert S, de Rond L, Tang VA, Tertel T, Yan X, Wauben MHM, Nolan JP, Jones JC, Nieuwland R, van der Pol E. A compendium of single extracellular vesicle flow cytometry. J Extracell Vesicles 2023; 12:e12299. [PMID: 36759917 PMCID: PMC9911638 DOI: 10.1002/jev2.12299] [Citation(s) in RCA: 26] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Revised: 11/29/2022] [Accepted: 12/17/2022] [Indexed: 02/11/2023] Open
Abstract
Flow cytometry (FCM) offers a multiparametric technology capable of characterizing single extracellular vesicles (EVs). However, most flow cytometers are designed to detect cells, which are larger than EVs. Whereas cells exceed the background noise, signals originating from EVs partly overlap with the background noise, thereby making EVs more difficult to detect than cells. This technical mismatch together with complexity of EV-containing fluids causes limitations and challenges with conducting, interpreting and reproducing EV FCM experiments. To address and overcome these challenges, researchers from the International Society for Extracellular Vesicles (ISEV), International Society for Advancement of Cytometry (ISAC), and the International Society on Thrombosis and Haemostasis (ISTH) joined forces and initiated the EV FCM working group. To improve the interpretation, reporting, and reproducibility of future EV FCM data, the EV FCM working group published an ISEV position manuscript outlining a framework of minimum information that should be reported about an FCM experiment on single EVs (MIFlowCyt-EV). However, the framework contains limited background information. Therefore, the goal of this compendium is to provide the background information necessary to design and conduct reproducible EV FCM experiments. This compendium contains background information on EVs, the interaction between light and EVs, FCM hardware, experimental design and preanalytical procedures, sample preparation, assay controls, instrument data acquisition and calibration, EV characterization, and data reporting. Although this compendium focuses on EVs, many concepts and explanations could also be applied to FCM detection of other particles within the EV size range, such as bacteria, lipoprotein particles, milk fat globules, and viruses.
Collapse
Affiliation(s)
- Joshua A Welsh
- Translational Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Ger J A Arkesteijn
- Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - Michel Bremer
- Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Michael Cimorelli
- Vesicle Observation Center, Amsterdam University Medical Centers, Amsterdam, The Netherlands
- Experimental Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, The Netherlands
- Department of Chemical Engineering, Drexel University, Philadelphia, Pennsylvania, USA
| | - Françoise Dignat-George
- Aix Marseille Univ, INSERM, INRAE, C2VN, UFR de Pharmacie, Marseille, France
- Hematology and Vascular Biology Department, CHU La Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France
| | - Bernd Giebel
- Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - André Görgens
- Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
- Clinical Research Center, Department for Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
- Evox Therapeutics Ltd, Oxford, UK
| | - An Hendrix
- Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium
| | - Martine Kuiper
- Vesicle Observation Center, Amsterdam University Medical Centers, Amsterdam, The Netherlands
- Experimental Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, The Netherlands
- Biomedical Engineering & Physics, Amsterdam University Medical Centers, Amsterdam, The Netherlands
- Dutch Metrology Institute, VSL, Delft, The Netherlands
| | - Romaric Lacroix
- Aix Marseille Univ, INSERM, INRAE, C2VN, UFR de Pharmacie, Marseille, France
- Hematology and Vascular Biology Department, CHU La Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France
| | - Joanne Lannigan
- Flow Cytometry Support Services, LLC, Arlington, Virginia, USA
| | - Ton G van Leeuwen
- Vesicle Observation Center, Amsterdam University Medical Centers, Amsterdam, The Netherlands
- Biomedical Engineering & Physics, Amsterdam University Medical Centers, Amsterdam, The Netherlands
- Amsterdam Cardiovascular Sciences, Atherosclerosis and Ischemic Syndromes, Amsterdam, The Netherlands
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands
| | - Estefanía Lozano-Andrés
- Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - Shoaib Rao
- Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Stéphane Robert
- Aix Marseille Univ, INSERM, INRAE, C2VN, UFR de Pharmacie, Marseille, France
- Hematology and Vascular Biology Department, CHU La Conception, Assistance Publique-Hôpitaux de Marseille, Marseille, France
| | - Leonie de Rond
- Vesicle Observation Center, Amsterdam University Medical Centers, Amsterdam, The Netherlands
- Experimental Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, The Netherlands
- Biomedical Engineering & Physics, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | - Vera A Tang
- Flow Cytometry & Virometry Core Facility, Faculty of Medicine, Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, Ontario, Canada
| | - Tobias Tertel
- Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - Xiaomei Yan
- MOE Key Laboratory of Spectrochemical Analysis & Instrumentation, Key Laboratory for Chemical Biology of Fujian Province, Department of Chemical Biology, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, Fujian, People's Republic of China
| | - Marca H M Wauben
- Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - John P Nolan
- Scintillon Institute, San Diego, California, USA
- Cellarcus Biosciences, San Diego, California, USA
| | - Jennifer C Jones
- Translational Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Rienk Nieuwland
- Vesicle Observation Center, Amsterdam University Medical Centers, Amsterdam, The Netherlands
- Experimental Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, The Netherlands
- Amsterdam Cardiovascular Sciences, Atherosclerosis and Ischemic Syndromes, Amsterdam, The Netherlands
| | - Edwin van der Pol
- Vesicle Observation Center, Amsterdam University Medical Centers, Amsterdam, The Netherlands
- Experimental Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, The Netherlands
- Biomedical Engineering & Physics, Amsterdam University Medical Centers, Amsterdam, The Netherlands
- Amsterdam Cardiovascular Sciences, Atherosclerosis and Ischemic Syndromes, Amsterdam, The Netherlands
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands
| |
Collapse
|
7
|
Burnie J, Persaud AT, Thaya L, Liu Q, Miao H, Grabinsky S, Norouzi V, Lusso P, Tang VA, Guzzo C. P-selectin glycoprotein ligand-1 (PSGL-1/CD162) is incorporated into clinical HIV-1 isolates and can mediate virus capture and subsequent transfer to permissive cells. Retrovirology 2022; 19:9. [PMID: 35597982 PMCID: PMC9123692 DOI: 10.1186/s12977-022-00593-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Accepted: 04/21/2022] [Indexed: 11/16/2022] Open
Abstract
Background P-selectin glycoprotein ligand-1 (PSGL-1/CD162) has been studied extensively for its role in mediating leukocyte rolling through interactions with its cognate receptor, P-selectin. Recently, PSGL-1 was identified as a novel HIV-1 host restriction factor, particularly when expressed at high levels in the HIV envelope. Importantly, while the potent antiviral activity of PSGL-1 has been clearly demonstrated in various complementary model systems, the breadth of PSGL-1 incorporation across genetically diverse viral isolates and clinical isolates has yet to be described. Additionally, the biological activity of virion-incorporated PSGL-1 has also yet to be shown. Results Herein we assessed the levels of PSGL-1 on viruses produced through transfection with various amounts of PSGL-1 plasmid DNA (0–250 ng), compared to levels of PSGL-1 on viruses produced through infection of T cell lines and primary PBMC. We found that very low levels of PSGL-1 plasmid DNA (< 2.5 ng/well) were necessary to generate virus models that could closely mirror the phenotype of viruses produced via infection of T cells and PBMC. Unique to this study, we show that PSGL-1 is incorporated in a broad range of HIV-1 and SIV isolates and that virions with incorporated PSGL-1 are detectable in plasma from viremic HIV-1-infected individuals, corroborating the relevance of PSGL-1 in natural infection. Additionally, we show that PSGL-1 on viruses can bind its cognate selectin receptors, P-, E-, and L-selectins. Finally, we show viruses with endogenous levels of PSGL-1 can be captured by P-selectin and transferred to HIV-permissive bystander cells, highlighting a novel role for PSGL-1 in HIV-1 infection. Notably, viruses which contained high levels of PSGL-1 were noninfectious in our hands, in line with previous findings reporting the potent antiviral activity of PSGL-1. Conclusions Our results indicate that levels of PSGL-1 incorporation into virions can vary widely among model systems tested, and that careful tailoring of plasmid levels is required to recapitulate physiological systems when using pseudovirus models. Taken together, our data suggest that PSGL-1 may play diverse roles in the physiology of HIV-1 infection, particularly due to the functionally active state of PSGL-1 on virion surfaces and the breadth of PSGL-1 incorporation among a wide range of viral isolates. Supplementary Information The online version contains supplementary material available at 10.1186/s12977-022-00593-5.
Collapse
Affiliation(s)
- Jonathan Burnie
- Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON, Canada.,Department of Cell and Systems Biology, University of Toronto, 25 Harbord Street, Toronto, ON, Canada
| | - Arvin Tejnarine Persaud
- Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON, Canada.,Department of Cell and Systems Biology, University of Toronto, 25 Harbord Street, Toronto, ON, Canada
| | - Laxshaginee Thaya
- Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON, Canada.,Department of Cell and Systems Biology, University of Toronto, 25 Harbord Street, Toronto, ON, Canada
| | - Qingbo Liu
- Viral Pathogenesis Section, Laboratory of Immunoregulation (LIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Huiyi Miao
- Viral Pathogenesis Section, Laboratory of Immunoregulation (LIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Stephen Grabinsky
- Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON, Canada
| | - Vanessa Norouzi
- Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON, Canada
| | - Paolo Lusso
- Viral Pathogenesis Section, Laboratory of Immunoregulation (LIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Vera A Tang
- Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, Flow Cytometry and Virometry Core Facility, University of Ottawa, Ottawa, ON, Canada
| | - Christina Guzzo
- Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON, Canada. .,Department of Cell and Systems Biology, University of Toronto, 25 Harbord Street, Toronto, ON, Canada.
| |
Collapse
|
8
|
Aspland AM, Douagi I, Filby A, Jellison ER, Martinez L, Shinko D, Smith AL, Tang VA, Thornton S. Biosafety during a pandemic: shared resource laboratories rise to the challenge. Cytometry A 2021; 99:68-80. [PMID: 33289290 PMCID: PMC7753791 DOI: 10.1002/cyto.a.24280] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Revised: 11/21/2020] [Accepted: 11/29/2020] [Indexed: 01/19/2023]
Abstract
Biosafety has always been an important aspect of daily work in any research institution, particularly for cytometry Shared Resources Laboratories (SRLs). SRLs are common‐use spaces that facilitate the sharing of knowledge, expertise, and ideas. This sharing inescapably involves contact and interaction of all those within this working environment on a daily basis. The current pandemic caused by SARS‐CoV‐2 has prompted the re‐evaluation of many policies governing the operations of SRLs. Here we identify and review the unique challenges SRLs face in maintaining biosafety standards, highlighting the potential risks associated with not only cytometry instrumentation and samples, but also the people working with them. We propose possible solutions to safety issues raised by the COVID‐19 pandemic and provide tools for facilities to adapt to evolving guidelines and future challenges.
Collapse
Affiliation(s)
- Avrill M Aspland
- Sydney Cytometry Core Research Facility, Centenary Institute, The University of Sydney, Sydney, New South Wales, Australia
| | - Iyadh Douagi
- Flow Cytometry Section, Research Technologies Branch, NIAID, NIH, Bethesda, Maryland, USA
| | - Andrew Filby
- Innovation, Methodology and Application Research Theme, Newcastle University, Newcastle upon Tyne, UK
| | - Evan R Jellison
- Department of Immunology, UCONN School of Medicine, Farmington, Connecticut, USA
| | - Lola Martinez
- Biotechnology Programme, Flow Cytometry Core Unit, Spanish National Cancer Research Center (CNIO), Madrid, Spain
| | - Diana Shinko
- Sydney Cytometry Core Research Facility, Centenary Institute, The University of Sydney, Sydney, New South Wales, Australia
| | - Adrian L Smith
- Sydney Cytometry Core Research Facility, Centenary Institute, The University of Sydney, Sydney, New South Wales, Australia
| | - Vera A Tang
- Faculty of Medicine, Department of Biochemistry, Microbiology, and Immunology, Flow Cytometry and Virometry Core Facility, University of Ottawa, Ottawa, Ontario, Canada
| | - Sherry Thornton
- Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati Medical Center, Cincinnati, Ohio, USA
| |
Collapse
|
9
|
Welsh JA, Tang VA, van der Pol E, Görgens A. MIFlowCyt-EV: The Next Chapter in the Reporting and Reliability of Single Extracellular Vesicle Flow Cytometry Experiments. Cytometry A 2020; 99:365-368. [PMID: 33200505 DOI: 10.1002/cyto.a.24268] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Revised: 10/26/2020] [Accepted: 11/12/2020] [Indexed: 12/22/2022]
Affiliation(s)
- Joshua A Welsh
- Translational Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
| | - Vera A Tang
- Faculty of Medicine, Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Flow Cytometry and Virometry Core Facility, Ottawa, Ontario, Canada
| | - Edwin van der Pol
- Biomedical Engineering and Physics, Amsterdam UMC location AMC, University of Amsterdam, Amsterdam, The Netherlands.,Laboratory Experimental Clinical Chemistry, Amsterdam UMC location AMC, University of Amsterdam, Amsterdam, The Netherlands.,Vesicle Observation Center, Amsterdam UMC location AMC, University of Amsterdam, Amsterdam, The Netherlands
| | - André Görgens
- Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.,Clinical Research Center, Department for Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.,Evox Therapeutics Ltd, Oxford, UK
| |
Collapse
|
10
|
Burnie J, Tang VA, Welsh JA, Persaud AT, Thaya L, Jones JC, Guzzo C. Flow Virometry Quantification of Host Proteins on the Surface of HIV-1 Pseudovirus Particles. Viruses 2020; 12:v12111296. [PMID: 33198254 PMCID: PMC7697180 DOI: 10.3390/v12111296] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Revised: 11/04/2020] [Accepted: 11/09/2020] [Indexed: 12/20/2022] Open
Abstract
The HIV-1 glycoprotein spike (gp120) is typically the first viral antigen that cells encounter before initiating immune responses, and is often the sole target in vaccine designs. Thus, characterizing the presence of cellular antigens on the surfaces of HIV particles may help identify new antiviral targets or impact targeting of gp120. Despite the importance of characterizing proteins on the virion surface, current techniques available for this purpose do not support high-throughput analysis of viruses, and typically only offer a semi-quantitative assessment of virus-associated proteins. Traditional bulk techniques often assess averages of viral preparations, which may mask subtle but important differences in viral subsets. On the other hand, microscopy techniques, which provide detail on individual virions, are difficult to use in a high-throughput manner and have low levels of sensitivity for antigen detection. Flow cytometry is a technique that traditionally has been used for rapid, high-sensitivity characterization of single cells, with limited use in detecting viruses, since the small size of viral particles hinders their detection. Herein, we report the detection and surface antigen characterization of HIV-1 pseudovirus particles by light scattering and fluorescence with flow cytometry, termed flow virometry for its specific application to viruses. We quantified three cellular proteins (integrin α4β7, CD14, and CD162/PSGL-1) in the viral envelope by directly staining virion-containing cell supernatants without the requirement of additional processing steps to distinguish virus particles or specific virus purification techniques. We also show that two antigens can be simultaneously detected on the surface of individual HIV virions, probing for the tetraspanin marker, CD81, in addition to α4β7, CD14, and CD162/PSGL-1. This study demonstrates new advances in calibrated flow virometry as a tool to provide sensitive, high-throughput characterization of the viral envelope in a more efficient, quantitative manner than previously reported techniques.
Collapse
Affiliation(s)
- Jonathan Burnie
- Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON M1C 1A4, Canada; (J.B.); (A.T.P.); (L.T.)
- Department of Cell and Systems Biology, University of Toronto, 25 Harbord Street, Toronto, ON M5S 3G5, Canada
| | - Vera A. Tang
- Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Flow Cytometry and Virometry Core Facility, Ottawa, ON K1H 8M5, Canada;
| | - Joshua A. Welsh
- Translational Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; (J.A.W.); (J.C.J.)
| | - Arvin T. Persaud
- Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON M1C 1A4, Canada; (J.B.); (A.T.P.); (L.T.)
| | - Laxshaginee Thaya
- Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON M1C 1A4, Canada; (J.B.); (A.T.P.); (L.T.)
- Department of Cell and Systems Biology, University of Toronto, 25 Harbord Street, Toronto, ON M5S 3G5, Canada
| | - Jennifer C. Jones
- Translational Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; (J.A.W.); (J.C.J.)
| | - Christina Guzzo
- Department of Biological Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, ON M1C 1A4, Canada; (J.B.); (A.T.P.); (L.T.)
- Department of Cell and Systems Biology, University of Toronto, 25 Harbord Street, Toronto, ON M5S 3G5, Canada
- Correspondence: ; Tel.: +1-(416)-287-7436
| |
Collapse
|
11
|
Czechowska K, Lannigan J, Aghaeepour N, Back JB, Begum J, Behbehani G, Bispo C, Bitoun D, Fernández AB, Boova ST, Brinkman RR, Ciccolella CO, Cotleur B, Davies D, Dela Cruz GV, Del Rio-Guerra R, Des Lauriers-Cox AM, Douagi I, Dumrese C, Bonilla Escobar DL, Estevam J, Ewald C, Fossum A, Gaudillière B, Green C, Groves C, Hall C, Haque Y, Hedrick MN, Hogg K, Hsieh EWY, Irish J, Lederer J, Leipold M, Lewis-Tuffin LJ, Litwin V, Lopez P, Nasdala I, Nedbal J, Ohlsson-Wilhelm BM, Price KM, Rahman AH, Rayanki R, Rieger AM, Robinson JP, Shapiro H, Sun YS, Tang VA, Tesfa L, Telford WG, Walker R, Welsh JA, Wheeler P, Tárnok A. Cyt-Geist: Current and Future Challenges in Cytometry: Reports of the CYTO 2019 Conference Workshops. Cytometry A 2020; 95:1236-1274. [PMID: 31833655 DOI: 10.1002/cyto.a.23941] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Affiliation(s)
| | - Joanne Lannigan
- Flow Cytometry Support Services, LLC, Alexandria, Virginia.,Flow Cytometry Core, University of Virginia, School of Medicine, Charlottesville, Virginia
| | - Nima Aghaeepour
- Department of Anesthesiology, Department of Biomedical Data Sciences, Department of Pediatrics, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford University, Stanford, California
| | - Jessica B Back
- Department of Oncology, Wayne State University, Detroit, Michigan
| | - Julfa Begum
- Flow Cytometry Facility, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Greg Behbehani
- Wexner Medical Center, Ohio State University, Columbus, Ohio
| | - Cláudia Bispo
- Parnassus Flow Cytometry Core, University of California San Francisco, San Francisco, California.,ISAC SRL Emerging Leader, Arlington, Virginia
| | - Daniel Bitoun
- EMA Regional Marketing, BD Lifesciences, International Office, Belgium
| | - Alfonso Blanco Fernández
- UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin, Ireland
| | - Samuel Tony Boova
- High Burden HIV Global Markets, Beckman Coulter, Inc., Miami, Florida
| | - Ryan Remy Brinkman
- Medical Genetics, University of British Columbia and British Columbia Cancer, Vancouver, British Columbia, Canada.,Cytapex Bioinformatics Inc., Vancouver, British Columbia, Canada
| | | | | | - Derek Davies
- Science Technology Platform Training Lead, Francis Crick Institute, London, UK
| | - Gelo Victoriano Dela Cruz
- Novo Nordisk Foundation Center for Stem Cell Biology - DanStem, Flow Cytometry Platform, Copenhagen, Denmark
| | - Roxana Del Rio-Guerra
- Flow Cytometry and Cell Sorting Facility, Larner College of Medicine, University of Vermont, Burlington, Vermont
| | | | - Iyadh Douagi
- Flow Cytometry Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
| | - Claudia Dumrese
- Cytometry Facility, University of Zürich, Zürich, Switzerland
| | | | - Jose Estevam
- Center of Biomarker Innovation and Development, Takeda Pharmaceuticals, Cambridge, Massachusetts
| | - Christina Ewald
- Cytometry Facility Senior Scientist, University of Zürich, Zürich, Switzerland
| | - Anna Fossum
- Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark
| | - Brice Gaudillière
- Anesthesiology Department, Stanford University, Stanford, California
| | - Cherie Green
- Flow Cytometry Biomarkers Development Sciences, Genentech, Inc., San Francisco, California
| | - Christopher Groves
- Cytometry/Dynamic Omics in R&D Antibody Discovery and Protein Engineering, Astra Zeneca, Gaithersburg, Maryland
| | - Christopher Hall
- ISAC SRL Emerging Leader, Arlington, Virginia.,Cytometry Core Facility, Wellcome Sanger Institute, Hinxton, UK
| | - Yasmin Haque
- Flow Cytometry Facility, Department of Immunobiology and Infectious Diseases, King's College London, London, UK
| | | | - Karen Hogg
- Imaging and Cytometry Laboratory, Bioscience Technology Facility, Department of Biology, University of York, York, UK
| | - Elena W Y Hsieh
- Department of Immunology and Microbiology, Department of Pediatrics, Division of Allergy and Immunology, School of Medicine, University of Colorado, Aurora, Colorado
| | - Jonathan Irish
- Cancer & Immunology Core and Mass Cytometry Center of Excellence, Vanderbilt University, Nashville, Tennessee
| | - James Lederer
- Department of Surgery (Immunology), Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts
| | - Michael Leipold
- Human Immune Monitoring Center (HIMC), Stanford University, Stanford, California
| | - Laura J Lewis-Tuffin
- Microscopy and Flow Cytometry Shared Resource, Mayo Clinic, Jacksonville, Florida
| | - Virginia Litwin
- Caprion Biosciences, Inc., Immunology, Montreal, Quebec, Canada
| | - Peter Lopez
- Cytometry and Cell Sorting Laboratory, New York University School of Medicine, New York, New York
| | | | - Jakub Nedbal
- Physics Department, King's College London, London, UK.,ISAC Marylou Ingram Scholar, Arlington, Virginia
| | | | - Kylie M Price
- Hugh Green Cytometry Centre, Malaghan Institute of Medical Research, Wellington, New Zealand
| | - Adeeb H Rahman
- Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York.,Dept. of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Radhika Rayanki
- Cytometry/Dynamic Omics in R&D Antibody Discovery and Protein Engineering, Astra Zeneca, Gaithersburg, Maryland
| | - Aja M Rieger
- ISAC SRL Emerging Leader, Arlington, Virginia.,University of Alberta, Flow Cytometry Facility, Faculty of Medicine and Dentistry, Alberta, Canada
| | - J Paul Robinson
- College of Veterinary Medicine and Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana
| | | | | | - Vera A Tang
- University of Ottawa, Flow Cytometry and Virometry Core Facility, Ottawa, Canada.,Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada
| | - Lydia Tesfa
- Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York
| | - William G Telford
- Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Center Institute, National Institutes of Health, Bethesda, Maryland
| | - Rachael Walker
- Flow Cytometry Core Facility, Babraham Institute, Cambridge, UK
| | - Joshua A Welsh
- ISAC Marylou Ingram Scholar, Arlington, Virginia.,Laboratory of Pathology, Translational Nanobiology Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Paul Wheeler
- Flow Cytometry, Luminex Corporation, Peterborough, UK
| | - Attila Tárnok
- Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig, Leipzig, Germany.,Department Therapy Validation, Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany
| |
Collapse
|
12
|
Welsh JA, Jones JC, Tang VA. Fluorescence and Light Scatter Calibration Allow Comparisons of Small Particle Data in Standard Units across Different Flow Cytometry Platforms and Detector Settings. Cytometry A 2020; 97:592-601. [PMID: 32476280 PMCID: PMC8482305 DOI: 10.1002/cyto.a.24029] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2020] [Revised: 03/27/2020] [Accepted: 04/03/2020] [Indexed: 12/28/2022]
Abstract
Flow cytometers have been utilized for the analysis of submicron-sized particles since the late 1970s. Initially, virus analyses preceded extracellular vesicle (EV), which began in the 1990s. Despite decades of documented use, the lack of standardization in data reporting has resulted in a growing body of literature that cannot be easily interpreted, validated, or reproduced. This has made it difficult for objective assessments of both assays and instruments, in-turn leading to significant hindrances in scientific progress, specifically in the study of EVs, where the phenotypic analysis of these submicron-sized vesicles is becoming common-place in every biomedical field. Methods for fluorescence and light scatter standardization are well established and the reagents to perform these analyses are commercially available. However, fluorescence and light scatter calibration are not widely adopted by the small particle community as methods to standardize flow cytometry (FCM) data. In this proof-of-concept study carried out as a resource for use at the CYTO2019 workshop, we demonstrate for the first-time simultaneous fluorescence and light scatter calibration of small particle data to show the ease and feasibility of this method for standardized FCM data reporting. This data was acquired using standard configuration commercial flow cytometers, with commercially available materials, published methods, and freely available software tools. We show that application of light scatter, fluorescence, and concentration calibration can result in highly concordant data between FCM platforms independent of instrument collection angle, gain/voltage settings, and flow rate; thus, providing a means of cross comparison in standard units. © 2020 International Society for Advancement of Cytometry.
Collapse
Affiliation(s)
- Joshua A. Welsh
- Translational Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892
| | - Jennifer C. Jones
- Translational Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, 20892
| | - Vera A. Tang
- Faculty of Medicine, Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Flow Cytometry and Virometry Core Facility, Ottawa, Ontario, K1H 8M5, Canada
| |
Collapse
|
13
|
Brittain GC, Chen YQ, Martinez E, Tang VA, Renner TM, Langlois MA, Gulnik S. A Novel Semiconductor-Based Flow Cytometer with Enhanced Light-Scatter Sensitivity for the Analysis of Biological Nanoparticles. Sci Rep 2019; 9:16039. [PMID: 31690751 PMCID: PMC6831566 DOI: 10.1038/s41598-019-52366-4] [Citation(s) in RCA: 45] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2019] [Accepted: 10/15/2019] [Indexed: 01/20/2023] Open
Abstract
The CytoFLEX is a novel semiconductor-based flow cytometer that utilizes avalanche photodiodes, wavelength-division multiplexing, enhanced optics, and diode lasers to maximize light capture and minimize optical and electronic noise. Due to an increasing interest in the use of extracellular vesicles (EVs) as disease biomarkers, and the growing desire to use flow cytometry for the analyses of biological nanoparticles, we assessed the light-scatter sensitivity of the CytoFLEX for small-particle detection. We found that the CytoFLEX can fully resolve 70 nm polystyrene and 98.6 nm silica beads by violet side scatter (VSSC). We further analyzed the detection limit for biological nanoparticles, including viruses and EVs, and show that the CytoFLEX can detect viruses down to 81 nm and EVs at least as small as 65 nm. Moreover, we could immunophenotype EV surface antigens, including directly in blood and plasma, demonstrating the double labeling of platelet EVs with CD61 and CD9, as well as triple labeling with CD81 for an EV subpopulation in one donor. In order to assess the refractive indices (RIs) of the viruses and EVs, we devised a new method to inversely calculate the RIs using the intensity vs. size data together with Mie-theory scatter efficiencies scaled to reference-particle measurements. Each of the viruses tested had an equivalent RI, approximately 1.47 at 405 nm, which suggests that flow cytometry can be more broadly used to easily determine virus sizes. We also found that the RIs of EVs increase as the particle diameters decrease below 150 nm, increasing from 1.37 for 200 nm EVs up to 1.61 for 65 nm EVs, expanding the lower range of EVs that can be detected by light scatter. Overall, we demonstrate that the CytoFLEX has an unprecedented level of sensitivity compared to conventional flow cytometers. Accordingly, the CytoFLEX can be of great benefit to virology and EV research, and will help to expand the use of flow cytometry for minimally invasive liquid biopsies by allowing for the direct analysis of antigen expression on biological nanoparticles within patient samples, including blood, plasma, urine and bronchoalveolar lavages.
Collapse
Affiliation(s)
- George C Brittain
- Beckman Coulter Life Sciences, Life Science Research, Miami, FL, USA
| | - Yong Q Chen
- Beckman Coulter Life Sciences, Life Science Research, Miami, FL, USA
| | - Edgar Martinez
- Beckman Coulter Life Sciences, Particle Characterization, Miami, FL, USA
| | - Vera A Tang
- University of Ottawa Flow Cytometry and Virometry Core Facility, Ottawa, Canada.,Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada
| | - Tyler M Renner
- Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada
| | - Marc-André Langlois
- University of Ottawa Flow Cytometry and Virometry Core Facility, Ottawa, Canada.,Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada.,uOttawa Center for Infection, Immunity and Inflammation (CI3), University of Ottawa, Ottawa, Canada
| | - Sergei Gulnik
- Beckman Coulter Life Sciences, Life Science Research, Miami, FL, USA.
| |
Collapse
|
14
|
Ruzicka M, Xiao F, Abujrad H, Al-Rewashdy Y, Tang VA, Langlois MA, Sorisky A, Ooi TC, Burger D. Effect of hemodialysis on extracellular vesicles and circulating submicron particles. BMC Nephrol 2019; 20:294. [PMID: 31375072 PMCID: PMC6679543 DOI: 10.1186/s12882-019-1459-y] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Accepted: 07/08/2019] [Indexed: 01/17/2023] Open
Abstract
Background Although hemodialysis is a highly effective treatment for diffusive clearance of low molecular weight uremic toxins, its effect on circulating extracellular vesicles and submicron particles is less clear. The purpose of this study was to examine the impact of hemodialysis on circulating levels of submicron particles. Methods Plasma samples from patients were collected immediately before and after the mid-week hemodialysis session. Total submicron particles were assessed by nanoparticle tracking analysis and levels of endothelial (CD144+), platelet (CD41+), leukocyte (CD45+), and total (Annexin V+) membrane microparticles (MPs) were assessed by flow cytometry. Results Total submicron particle number was significantly lower post-dialysis with reductions in particles < 40 nm, 40–100 nm, and 100–1000 nm in size. Circulating annexin V+ MPs, platelet MPs, leukocyte MPs, and endothelial MPs were all reduced following dialysis. Assessment of protein markers suggested that extracellular vesicles were not present in the dialysate, but rather adsorbed to the dialysis membrane. Conclusions In summary, hemodialysis is associated with reductions in circulating submicron particles including membrane MPs. Accordingly, there may be significant interdialytic variation in circulating submicron particles. Investigators interested in measuring extracellular vesicles in patients undergoing hemodialysis should therefore carefully consider the timing of biosampling.
Collapse
Affiliation(s)
- Marcel Ruzicka
- Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, 2513-451 Smyth Road, Ottawa, Ontario, K1H 8M5, Canada. .,Division of Nephrology, University of Ottawa, The Ottawa Hospital, Riverside Campus, Room 5-21, Riverside 1967, Ottawa, Ontario, K1H 7W9, Canada. .,Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
| | - Fengxia Xiao
- Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, 2513-451 Smyth Road, Ottawa, Ontario, K1H 8M5, Canada
| | - Hussein Abujrad
- Division of Endocrinology and Metabolism, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Yasamin Al-Rewashdy
- Division of Endocrinology and Metabolism, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Vera A Tang
- uOttawa Flow Cytometry & Virometry Core Facility, Ottawa, Ontario, Canada.,Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada
| | - Marc-André Langlois
- uOttawa Flow Cytometry & Virometry Core Facility, Ottawa, Ontario, Canada.,Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada
| | - Alexander Sorisky
- Division of Endocrinology and Metabolism, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.,Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada
| | - Teik Chye Ooi
- Division of Endocrinology and Metabolism, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Dylan Burger
- Kidney Research Centre, Ottawa Hospital Research Institute, University of Ottawa, 2513-451 Smyth Road, Ottawa, Ontario, K1H 8M5, Canada. .,Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada.
| |
Collapse
|
15
|
Balathasan L, Tang VA, Yadollahi B, Brun J, Labelle M, Lefebvre C, Swift SL, Stojdl DF. Activating Peripheral Innate Immunity Enables Safe and Effective Oncolytic Virotherapy in the Brain. Mol Ther Oncolytics 2017; 7:45-56. [PMID: 29062886 PMCID: PMC5645178 DOI: 10.1016/j.omto.2017.09.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/10/2017] [Accepted: 09/08/2017] [Indexed: 11/29/2022]
Abstract
The oncolytic mutant vesicular stomatitis virus VSVΔ51 achieves robust efficacy in multiple extracranial tumor models. Yet for malignancies of the brain, direct intratumoral infusion of VSVΔ51 causes lethal virus-induced neuropathology. Here, we have developed a novel therapeutic regime that uses peripheral immunization with a single sub-lethal dose of VSVΔ51 to establish an acute anti-viral state that enables the safe intracranial (IC) infusion of an otherwise lethal dose of VSVΔ51 within just 6 hr. Although type I interferons alone appeared insufficient to explain this protective phenotype, serum isolated at early time points from primed animals conferred protection against an IC dose of virus. Adaptive immune populations had minimal contributions. Finally, the therapeutic utility of this novel strategy was demonstrated by peripherally priming and intracranially treating mice bearing aggressive CT2A syngeneic astrocytomas with VSVΔ51. Approximately 25% of animals achieved complete regression of established tumors, with no signs of virus-induced neurological impairment. This approach may harness an early warning system in the brain that has evolved to protect the host against otherwise lethal neurotropic viral infections. We have exploited this protective mechanism to safely and efficaciously treat brain tumors with an otherwise neurotoxic virus, potentially widening the available treatment options for oncolytic virotherapy in the brain.
Collapse
Affiliation(s)
- Lukxmi Balathasan
- Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, ON K1H 8L1, Canada
| | - Vera A Tang
- Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, ON K1H 8L1, Canada
| | - Beta Yadollahi
- Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, ON K1H 8L1, Canada.,Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada
| | - Jan Brun
- Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, ON K1H 8L1, Canada
| | - Melanie Labelle
- Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, ON K1H 8L1, Canada
| | - Charles Lefebvre
- Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, ON K1H 8L1, Canada
| | - Stephanie L Swift
- Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, ON K1H 8L1, Canada
| | - David F Stojdl
- Children's Hospital of Eastern Ontario Research Institute, 401 Smyth Road, Ottawa, ON K1H 8L1, Canada.,Department of Biology, Microbiology and Immunology, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada.,Department of Pediatrics, University of Ottawa, 75 Laurier Ave. E., Ottawa, ON K1N 6N5, Canada
| |
Collapse
|
16
|
Tang VA, Renner TM, Varette O, Le Boeuf F, Wang J, Diallo JS, Bell JC, Langlois MA. Single-particle characterization of oncolytic vaccinia virus by flow virometry. Vaccine 2016; 34:5082-5089. [PMID: 27614781 DOI: 10.1016/j.vaccine.2016.08.074] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Revised: 07/27/2016] [Accepted: 08/23/2016] [Indexed: 12/28/2022]
Abstract
Vaccinia virus (VV) is an oncolytic virus that is currently being evaluated as a promising cancer vaccine in several phase I, II and III clinical trials. Although several quality control tests are performed on each new batch of virus, these do not routinely include a systematic characterization of virus particle homogeneity, or relate the infectious titer to the total number of submicron sized particles (SSPs) present in the sample. SSPs are comprised of infectious virus and non-infectious viral particles, but also cell contaminants derived from the virus isolation procedures, such as cellular vesicles and debris. Here we have employed flow virometry (FV) analysis and sorting to isolate and characterize distinct SSP populations in therapeutic oncolytic VV preparations. We show that VV preparations contain SSPs heterogeneous in size and include large numbers of non-infectious VV particles. Furthermore, we used FV to illustrate how VV has a propensity to aggregate over time and under various handling and storage procedures. Accordingly, we find that together the infectious titer, the total number of SSPs, the number of viral genomes and the level of particle aggregation in a sample constitute useful parameters that greatly facilitate inter-sample assessment of physical quality, and also provides a means to monitor sample deterioration over time. Additionally, we have successfully employed FV sorting to further isolate virus from other particles by identifying a lipophilic dye that preferentially stains VV over other SSPs in the sample. Overall, we demonstrate that FV is a fast and effective tool that can be used to perform quality, and consistency control assessments of oncolytic VV vaccine preparations.
Collapse
Affiliation(s)
- Vera A Tang
- University of Ottawa Flow Cytometry and Virometry Core Facility, Canada
| | - Tyler M Renner
- Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Canada
| | - Oliver Varette
- Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Canada; Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Canada
| | - Fabrice Le Boeuf
- Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Canada
| | - Jiahu Wang
- Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Canada
| | - Jean-Simon Diallo
- Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Canada; Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Canada
| | - John C Bell
- Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Canada; Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Canada
| | - Marc-André Langlois
- University of Ottawa Flow Cytometry and Virometry Core Facility, Canada; Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Canada.
| |
Collapse
|
17
|
Beug ST, Tang VA, LaCasse EC, Cheung HH, Beauregard CE, Brun J, Nuyens JP, Earl N, St-Jean M, Holbrook J, Dastidar H, Mahoney DJ, Ilkow C, Le Boeuf F, Bell JC, Korneluk RG. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat Biotechnol 2014; 32:182-90. [PMID: 24463573 PMCID: PMC5030098 DOI: 10.1038/nbt.2806] [Citation(s) in RCA: 94] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2013] [Accepted: 12/23/2013] [Indexed: 02/06/2023]
Abstract
Smac mimetic compounds (SMC), a class of drugs that sensitize cells to apoptosis by counteracting the activity of inhibitor of apoptosis (IAP) proteins, have proven safe in Phase I clinical trials in cancer patients. However, because SMCs act by enabling transduction of pro-apoptotic signals, SMC monotherapy may only be efficacious in the subset of patients whose tumors produce large quantities of death-inducing proteins such as inflammatory cytokines. As such, we reasoned that SMCs would synergize with agents that stimulate a potent yet safe “cytokine storm”. Here we show that oncolytic viruses and adjuvants such as poly(I:C) and CpG induce bystander death of cancer cells treated with SMCs that is mediated by interferon beta (IFNβ), tumor necrosis factor alpha (TNFα) and/or TNF-related apoptosis-inducing ligand (TRAIL). This combinatorial treatment resulted in tumor regression and extended survival in two mouse models of cancer. As these and other adjuvants have been proven safe in clinical trials, it may be worthwhile to explore their clinical efficacy in combination with SMCs.
Collapse
Affiliation(s)
- Shawn T Beug
- Solange Gauthier Karsh Molecular Genetics Laboratory, Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
| | - Vera A Tang
- Solange Gauthier Karsh Molecular Genetics Laboratory, Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
| | - Eric C LaCasse
- Solange Gauthier Karsh Molecular Genetics Laboratory, Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
| | - Herman H Cheung
- Solange Gauthier Karsh Molecular Genetics Laboratory, Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
| | - Caroline E Beauregard
- Solange Gauthier Karsh Molecular Genetics Laboratory, Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
| | - Jan Brun
- Solange Gauthier Karsh Molecular Genetics Laboratory, Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
| | - Jeffrey P Nuyens
- Solange Gauthier Karsh Molecular Genetics Laboratory, Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
| | - Nathalie Earl
- Solange Gauthier Karsh Molecular Genetics Laboratory, Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
| | - Martine St-Jean
- Solange Gauthier Karsh Molecular Genetics Laboratory, Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
| | - Janelle Holbrook
- Solange Gauthier Karsh Molecular Genetics Laboratory, Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada
| | - Himika Dastidar
- Alberta Children's Hospital Research Institute, Department of Microbiology, Immunology and Infectious Disease, University of Calgary, Calgary, Alberta, Canada
| | - Douglas J Mahoney
- Alberta Children's Hospital Research Institute, Department of Microbiology, Immunology and Infectious Disease, University of Calgary, Calgary, Alberta, Canada
| | - Carolina Ilkow
- Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - Fabrice Le Boeuf
- Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
| | - John C Bell
- 1] Centre for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. [2] Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada
| | - Robert G Korneluk
- 1] Solange Gauthier Karsh Molecular Genetics Laboratory, Apoptosis Research Centre, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada. [2] Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada
| |
Collapse
|
18
|
Beug ST, Tang VA, Cheung HC, Boeuf FL, Bell JC, LaCasse EC, Korneluk RG. 21. Cytokine 2013. [DOI: 10.1016/j.cyto.2013.06.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
19
|
Yebdri FB, VanGrevenynghe J, Tang VA, Goulet ML, Wu J, Stojdl DF, Hiscott J, Lin R. 289. Cytokine 2013. [DOI: 10.1016/j.cyto.2013.06.292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Ben Yebdri F, Van Grevenynghe J, Tang VA, Goulet ML, Wu JH, Stojdl DF, Hiscott J, Lin R. Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis. Mol Ther 2013; 21:2043-53. [PMID: 23985699 DOI: 10.1038/mt.2013.187] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2013] [Accepted: 07/30/2013] [Indexed: 12/15/2022] Open
Abstract
Preclinical and clinical trials demonstrated that use of oncolytic viruses (OVs) is a promising new therapeutic approach to treat multiple types of cancer. To further improve their viral oncolysis, experimental strategies are now combining OVs with different cytotoxic compounds. In this study, we investigated the capacity of triptolide - a natural anticancer molecule - to enhance vesicular stomatitis virus (VSV) oncolysis in OV-resistant cancer cells. Triptolide treatment increased VSV replication in the human prostate cancer cell line PC3 and in other VSV-resistant cells in a dose- and time-dependent manner in vitro and in vivo. Mechanistically, triptolide (TPL) inhibited the innate antiviral response by blocking type I interferon (IFN) signaling, downstream of IRF3 activation. Furthermore, triptolide-enhanced VSV-induced apoptosis in a dose-dependent fashion in VSV-resistant cells, as measured by annexin-V, cleaved caspase-3, and B-cell lymphoma 2 staining. In vivo, using the TSA mammary adenocarcinoma and PC3 mouse xenograft models, combination treatment with VSV and triptolide delayed tumor growth and prolonged survival of tumor-bearing animals by enhancing viral replication. Together, these results demonstrate that triptolide inhibition of IFN production sensitizes prostate cancer cells to VSV replication and virus-mediated apoptosis.
Collapse
Affiliation(s)
- Fethia Ben Yebdri
- Department of Medicine, Lady Davis Institute-Jewish General Hospital, McGill University, Montréal, Québec, Canada
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Tang VA, Rosenthal KL. Intravaginal infection with herpes simplex virus type-2 (HSV-2) generates a functional effector memory T cell population that persists in the murine genital tract. J Reprod Immunol 2010; 87:39-44. [PMID: 20688399 DOI: 10.1016/j.jri.2010.06.155] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2010] [Revised: 04/06/2010] [Accepted: 06/19/2010] [Indexed: 01/07/2023]
Abstract
Although the female genital tract is the main portal of entry for sexually transmitted infections in women, we still have limited understanding of the generation, maintenance and characteristics of memory T cells in the local tissue. Here, we utilized a mouse model of intravaginal HSV-2 infection and tetramers against the immunodominant HSV glycoprotein B epitope recognized by CD8+ T cells to examine the generation, maintenance and characteristics of anti-HSV memory T cells in the genital tract following acute infection. Our results show that the highest percentage of HSVgB-specific CD8+ T cells was found in the genital tract compared to the spleen or iliac lymphnode. Indeed, although the actual number of CD8+ T cells contracted following viral clearance, approximately one quarter of the CD8+ population that remained in the genital tissue was HSVgB-specific. Memory gB-tetramer+CD8 T cells in the genital tract were positive for CD127 and KLRG1 and negative for CD62L and CCR7, thus confirming that HSV-specific CD8 cells were effector memory T cells that lack the capacity for homing to lymphoid tissues. Functionally, both memory CD8+ and CD4+ HSV-specific populations in the genital tract produced IFNγ when stimulated in vitro and CD4+ cells also produced TNFα. Genital HSVgB-specific memory T cells expressed tissue-homing integrins CD103 (αE integrin) and CD49a (VLA-1 or α1 integrin). Our findings suggest that HSV-specific memory T cells are retained in the genital tract, poised to act as an early line of defense against future virus encounter.
Collapse
Affiliation(s)
- Vera A Tang
- Michael G. DeGroote Institute for Infectious Disease Research, Department of Pathology & Molecular Medicine, McMaster University, MDCL 4019, 1200 Main St. West, Hamilton, Ontario, Canada
| | | |
Collapse
|
22
|
Gillgrass AE, Tang VA, Towarnicki KM, Rosenthal KL, Kaushic C. Protection against genital herpes infection in mice immunized under different hormonal conditions correlates with induction of vagina-associated lymphoid tissue. J Virol 2005; 79:3117-26. [PMID: 15709031 PMCID: PMC548483 DOI: 10.1128/jvi.79.5.3117-3126.2005] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The present study was undertaken to examine the effect of the hormonal environment on immunization with an attenuated strain of herpes simplex virus type 2 (HSV-2 TK(-)) and subsequent protection against challenge. Ovariectomized mice were administered saline (S; control), estradiol (E(2)), progesterone (P(4)), or a combination of estradiol and progesterone (E+P) and immunized intravaginally (IVAG) with HSV-2 TK(-). Three weeks later, the immunized mice were challenged IVAG with wild-type HSV-2. Mice that were immunized following E treatment were not protected, whereas complete protection against the challenge was seen in mice from the S- and P(4)-treated groups. In the P(4)-treated group, 15% of mice developed chronic pathology following TK(-) immunization. Interestingly, about 40% of the E+P-treated mice were also protected. Upon examination of viral shedding in the vaginal secretions, it was clear that protection against challenge was dependent on the ability of the TK(-) virus to cause productive genital infection under different hormonal conditions. In the protected mice (the S and P groups and part of the E+P group), induced vagina-associated lymphoid tissues composed of CD11c(+) dendritic cells and CD3(+) and CD4(+) T cells were formed transiently in the vaginal lamina propria from day 2 to day 5 postchallenge. These aggregates were absent in the unprotected mice (the E group and part of the E+P group). Significant HSV-2-specific activation of lymphocytes was observed in the local draining lymph nodes of protected mice. This response was absent in the unprotected groups. High titers of gB-specific local immunoglobulin A (IgA) antibodies were present in the vaginal secretions of S- and P(4)-treated immunized mice following HSV-2 challenge. The S-treated group of mice also had high gB-specific IgG titers. These studies show that sex hormones modify the induction of protective immune responses following IVAG immunization.
Collapse
Affiliation(s)
- Amy E Gillgrass
- Department of Pathology, MDCL 4014, McMaster University, 1200 Main St. West, Hamilton, Ontario, Canada
| | | | | | | | | |
Collapse
|